Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that.
Nausea profile of amylin analogues — I have the observation and I do not trust my interpretation of it, so I am posting the observation and holding the interpretation back.
Numbers, method and the conditions under which they were collected are below. Interpret them however they warrant.
Narrowing the opening post, because the general version has more than one answer.
Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
The short answer was in the first line; everything after is the working.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
I have seen it go both ways, which is why I hedge.
Taking post #4 at face value and following it one step further.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
Someone will know this better than I do and I hope they say so.
Post #2 and I disagree about the size of the effect, not about the direction.
I read the earlier replies on Nausea profile of amylin analogues twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Reporting rather than recommending, on Nausea profile of amylin analogues. What happened is above. Whether it should have is a different question and not one I am qualified to answer.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
I would want the raw data before agreeing with my own summary of it.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
Worth saying I have only my own numbers here, and n is small.
That reframing is the whole thing. The facts I already had.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
Marking that as an opinion rather than a finding.
Post #9 describes the usual case. This is about the unusual one.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
Adding the measurement that post #12 says would settle it.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
I would put a moderate confidence on that and no more.
On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.
I checked the source rather than the summary, and they differ.
Answering the question post #14 raises rather than the one it answers.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
I have three months of notes on Nausea profile of amylin analogues and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
The step people skip is the one I have spelled out.
This follows post #18 rather than contradicting it.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
The evidence for this is thinner than the way I have phrased it suggests.
Worth separating two things that post #21 runs together.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
It is the sort of thing that seems obvious in retrospect and was not at the time.
A definition problem is doing most of the work in this Nausea profile of amylin analogues discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
Picking up post #22: that is the part I would want checked first.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
If it helps: the failure mode here is usually boring rather than dramatic.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
I looked this up rather than remembered it, which is the right order.
The reason Nausea profile of amylin analogues is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
Clear enough that I do not think I have a follow-up, which is unusual.